No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0101 Name of the Signatory :- Rajendra ChopraDesignation :- Company Secretary and Compliance Officer

Cipla Ltd.

06 Oct 2021

1513.80

0.25%

Cipla Q2 PAT seen up 20.3% YoY to Rs 793.4 cr: Prabhudas Lilladher

Moneycontrol

Net Sales are expected to increase by 4 percent Y-o-Y (down 5.5 percent Q-o-Q) to Rs 5,169.7 crore, according to Prabhudas Lilladher.

Cipla Ltd. has an average target of 1699.67 from 9 brokers.

Cipla Ltd.

05 Oct 2021

1513.80

0.25%

Corp. Note

CIPLA LTD. - 500087 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate …

BSE India

In compliance with the requirements of Regulation 39 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company vide intimation dated 22nd September, 2021 informed about the request received for issuance of duplicate share certificate in lieu of the loss of original share certificate by Mrs. Hasumati Wadia (legal heir) w/o Late Mr. Rasiklal J Wadia. In furtherance to the last intimation, it is hereby notified that vide approval of the Stakeholders Relationship Committee on 4th October, 2021, the Company has cancelled the original share certificates nos. 500537 and 659892 and has issued the duplicate share certificates.

pdf

Cipla Ltd.

04 Oct 2021

1513.80

0.25%

Company Update

Cipla Ltd - 500087 - Earnings Conference Call

BSE India

Please find enclosed schedule of Earnings Conference Call to be held on 26th October 2021.

pdf

Cipla Ltd.

04 Oct 2021

1513.80

0.25%

Cipla to sell Eli Lilly's Trulicity, Humalog diabetes treatments in India

Business Today

Lilly will transfer its rights in India to sell, promote and distribute its Trulicity and Humalog products, while continuing to maintain its existing operating model for the remaining portfolio of its products

Cipla Ltd. is trading above all available SMAs

Eli Lilly to transfer rights of two diabetes products to Cipla

Moneycontrol | 04 Oct 2021 2 more

Is Cipla Ltd. worth buying?

612 Votes:

Buy 75.98%

Sell 13.89%

Hold 10.13%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf